On 10th of June 2021, Dr Aaron Kesselheim, a member of the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee resigns over the agency’s controversial accelerated approval of Biogen’s drug Aducanumab.
All by Maria Riscado Ramos
On 10th of June 2021, Dr Aaron Kesselheim, a member of the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee resigns over the agency’s controversial accelerated approval of Biogen’s drug Aducanumab.